c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection

Vaccine

Volumn 27, Issue 35, 2009, Pages 4867-4873

  Hu, Dong Liang ^a   Narita, Kouji ^a   Hyodo, Mamoru ^b   Hayakawa, Yoshihiro ^b   Nakane, Akio ^a   Karaolis, David K R ^c,d  

^a HIROSAKI UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c Intragenics Research Institute   (United States)

^d Karagen Pharmaceuticals   (United States)

Author keywords

Adjuvant; c di GMP; Immunomodulator; MRSA; Staphylococcus aureus; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; CLUMPING FACTOR A; CYCLIC DIGUANYLATE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOMODULATING AGENT; STAPHYLOCOCCUS ENTEROTOXIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; COAGULASE; COLONY COUNT, MICROBIAL; CYCLIC GMP; ENTEROTOXINS; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LIVER; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED C57BL; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES;

EID: 67650438933     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.053     Document Type: Article

References (38)

1. Amikam D., and Benziman M. Cyclic diguanylic acid and cellulose synthesis in Agrobacterium tumefaciens. J Bacteriol 171 (1989) 6649-6655
2. Arrecubieta C., Asai T., Bayern M., Loughman A., Fitzgerald J.R., Shelton C.E., et al. The role of Staphylococcus aureus adhesins in the pathogenesis of ventricular assist device-related infections. J Infect Dis 193 (2006) 1109-1119
3. Arrecubieta C., Matsunaga I., Asai T., Naka Y., Deng M.C., and Lowy F.D. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 198 (2008) 571-575
4. Bavari S., Dyas B., and Ulrich R.G. Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A. J Infect Dis 174 (1996) 338-345
5. Brouillette E., Hyodo M., Hayakawa Y., Karaolis D.K.R., and Malouin F. 3′,5′-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob Agents Chemother 49 (2005) 3109-3113
6. D'Argenio D.A., Calfee M.W., Rainey P.B., and Pesci E.C. Autolysis and autoaggregation in Pseudomonas aeruginosa colony morphology mutants. J Bacteriol 184 (2002) 6481-6489
7. D'Argenio D.A., and Miller S.I. Cyclic di-GMP as a bacterial second messenger. Microbiology 150 (2004) 2497-2502
8. Dinges M.M., Orwin P.M., and Schlievert P.M. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13 (2000) 16-34
9. Foster T.J. Potential for vaccination against infections caused by Staphylococcus aureus. Vaccine 9 (1991) 221-227
10. Gampfer J., Thon V., Gulle H., Wolf H.M., and Eibl M.M. Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome. Vaccine 20 (2002) 1354-1364
11. Greenberg D.P., Ward J.I., and Bayer A.S. Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits. Infect Immun 55 (1987) 3030-3034
12. Hayakawa Y., Nagata R., Hirata A., Hyodo M., and Kawai R. A facile synthesis of cyclic bis(3′-5′) diguanylic acid. Tetrahedron 59 (2003) 6465-6471
13. Hu D.L., Cui J.C., Omoe K., Sashinami H., Yokomizo Y., Shinagawa K., et al. A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection. Infect Immun 73 (2005) 174-180
14. Hu D.L., Omoe K., Inoue F., Kasai T., Yasujima M., Shinagawa K., et al. Comparative prevalence of superantigenic toxin genes in meticillin-resistant and meticillin-susceptible Staphylococcus aureus isolates. J Med Microbiol 57 (2008) 1106-1112
15. Hu D.L., Omoe K., Sasaki S., Sashinami H., Sakuraba H., Yokomizo Y., et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis 188 (2003) 743-752
16. Hyodo M., and Hayakawa Y. An improved method for synthesizing cyclic bis(3′-5′)diguanylic acid (c-di-GMP). Bull Chem Soc Jpn 77 (2004) 2089-2093
17. Hyodo M., Hayakawa Y., and Karaolis D.K.R. Organic synthesis, chemical properties, and biological activities of cyclic bis(3′-5′)diguanylic acid (c-di-GMP) and its analogs. J Synth Org Chem Jpn 64 (2006) 359-370
18. Josefsson E., Hartford O., O'Brien L., Patti J.M., and Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184 (2001) 1572-1580
19. Karaolis D.K., Means T.K., Yang D., Takahashi M., Yoshimura T., Muraille E., et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 178 (2007) 2171-2181
20. Karaolis D.K., Newstead M.W., Zeng X., Hyodo M., Hayakawa Y., Bhan U., et al. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 75 (2007) 4942-4950
21. Karaolis D.K., Rashid M.H., Chythanya R., Luo W., Hyodo M., and Hayakawa Y. c-di-GMP (3′-5′-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation. Antimicrob Agents Chemother 49 (2005) 1029-1038
22. Karaolis D.K.R., Cheng K., Lipsky M., Elnabawi A., Catalano J., Hyodo M., et al. 3′,5′-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun 329 (2005) 40-45
23. Karaolis D.K.R., Means T.K., Yang D., Takahashi M., Yoshimura T., Muraille E., et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 178 (2007) 2171-2181
24. Karaolis D.K.R., Rashid M.H., Rajanna C., Luo W., Hyodo M., and Hayakawa Y. c-di-GMP (3′-5′-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation. Antimicrob Agents Chemother 49 (2005) 1029-1038
25. Karaolis D.K.R., Means T.K., Brouillette E., Talbot B.G., Yang D., Muraille E., et al. c-di-GMP is an immunostimulatory molecule with prophylactic and adjuvant activity. Presented at the General meeting of the American Society for Microbiology. Orlando, May 21-25 (2006)
26. Lee J.C. The prospects for developing a vaccine against Staphylococcus aureus. Trends Microbiol 4 (1996) 162-166
27. McCormick J.K., Hirt H., Dunny G.M., and Schlievert P.M. Pathogenic mechanisms of Enterococcal Endocarditis. Curr Infect Dis Rep 2 (2000) 315-321
28. Michie C.A. Staphylococcal vaccines. Trends Immunol 23 (2002) 461-463
29. Moreillon P., Entenza J.M., Francioli P., McDevitt D., Foster T.J., Francois P., et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 63 (1995) 4738-4743
30. Nilsson I.M., Verdrengh M., Ulrich R.G., Bavari S., and Tarkowski A. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect Dis 180 (1999) 1370-1373
31. Ogunniyi A.D., Paton J.C., Kirby A.C., McCullers J.A., Cook J., Hyodo M., et al. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine 26 (2008) 4676-4685
32. Que Y.A., Haefliger J.A., Piroth L., Francois P., Widmer E., Entenza J.M., et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med 201 (2005) 1627-1635
33. Rashid M.H., Rajanna C., Ali A., and Karaolis D.K.R. Identification of genes involved in the switch between the smooth and rugose phenotypes of Vibrio cholerae. FEMS Microbiol Lett 227 (2003) 113-119
34. Romling U., and Amikam D. Cyclic di-GMP as a second messenger. Curr Opin Microbiol 9 (2006) 218-228
35. Romling U., Gomelsky M., and Galperin M.Y. C-di-GMP: the dawning of a novel bacterial signalling system. Mol Microbiol 57 (2005) 629-639
36. Romling U., Rohde M., Olsen A., Normark S., and Reinkoster J. AgfD, the checkpoint of multicellular and aggregative behaviour in Salmonella typhimurium regulates at least two independent pathways. Mol Microbiol 36 (2000) 10-23
37. Ross P., Mayer R., Weinhouse H., Amikam D., Huggirat Y., Benziman M., et al. The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives. J Biol Chem 265 (1990) 18933-18943
38. Stiles B.G., Garza A.R., Ulrich R.G., and Boles J.W. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model. Infect Immun 69 (2001) 2031-2036